Antiplatelet Therapy for AIS Patients With Thrombocytopenia

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Sep 21, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how safe and effective a type of treatment called antiplatelet therapy is for patients who have had an acute ischemic stroke (AIS) and also have a low platelet count, a condition known as thrombocytopenia. Platelets are important for blood clotting, and this study aims to see if giving patients antiplatelet medications can help them recover better. The trial is currently recruiting participants who are over 18 years old and have experienced a stroke within the last week, along with a blood test showing a specific low platelet count.

If you or a family member is eligible and decides to participate, you will be given antiplatelet medications and monitored for three months to assess how well the treatment works and if there are any side effects. It's important to note that certain conditions, like severe kidney or liver problems, recent heart issues, or upcoming surgeries, may prevent someone from joining the study. This trial provides an opportunity to contribute to valuable research that could improve treatment options for patients with similar conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> 18 years old
• • Acute ischemic stroke or transient ischemic attack with onset \< 7 days
• • The last blood routine test before enrollment indicates platelet count \< 100 x 10\^9 and \> 30 x 10\^9
• Exclusion Criteria:
• • Chronic renal dysfunction (GFR \< 30ml/min) or severe hepatic injury
• • Indications for anticoagulation therapy, e.g. atrial fibrillation
• • Myocardial infarction within 6 months before enrollment or received percutaneous coronary intervention in the past
• • Have or plan to receive CEA or CAS in the following 3 months
• • Life expectancy less than 1 year
• • Plan to receive invasive surgery in the following 3 months and have high risk of uncontrollable bleeding
• • Pregnant or lactating women
• • Individuals identified by researchers as unsuitable for participation in the study due to other reasons.